Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ecms to accelerate anti-metastatic drug development
Active Project Grant Awarded Last action
- Award ID
- R44CA287881
- Recipient
-
Xylyx Bio, Inc. UEI N2N9KL2Y52X1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,561,023
Award facts
- Assistance listing
- 93.396 Cancer Biology Research
- Completion date 81% complete
- Place of performance
- Brooklyn, NY 11226, USA
Award details come from USAspending.gov.
Description
- Abstract
- Xylyx is developing a predictive multi-organ metastatic breast cancer cell-based assay platform to address the lack of in-vitro models of organotropic metastatic breast cancer in the market and accelerate drug development. Breast cancer is the most commonly diagnosed cancer in women, and most commonly metastasizes to bone, liver, and lung. Metastasis causes ~90% of cancer deaths, and metastatic breast cancer remains the second leading cause of death from cancer. Survival 5 years after diagnosis is 27%, and there is no cure. The extracellular matrix (ECM) in bone, liver, and lung is known to play critical roles in metastatic invasion and colonization. Animal models are poor predictors of metastasis in humans, and predictive in-vitro models of metastatic breast cancer are not commercially available, leaving a significant unmet need and market GAP/ opportunity for a physiologically-relevant in-vitro platform that enables high-fidelity cell-based phenotypic assays in organotropic breast cancer metastases. This sbir fast track will support development and validation studies for commercialization of a multi-organ metastatic breast cancer cell-based assay platform containing engineered organotropic metastases shown to be consistent with patient data. The technological innovation is the product's organotropic (bone, liver, lung) metastases stemming from proprietary methods for isolating and integrating acellular human tissue ecms with the tissue-specific properties of human tissues. Our approach integrates breast cancer patient-derived organoids in standardized multi-organ tissue-specific primary human ecms, enabling predictive assays on organotropic metastases - a major competitive advantage over all existing assays, which lack multi-organ human tissue-specificity. Our goal is to validate and commercialize a standard multi-organ metastatic breast cancer cell-based assay platform for predictive in-vitro modeling of metastatic breast cancer to reduce dependence on animal models and DE-risk preclinical decision-making. Specific aims: (1) perform multi-omics and histomorphologic profiling of engineered human breast cancer bone/liver/lung organotropic metastases; (2) evaluate histologic, molecular, phenotypic effects of cancer-associated fibroblasts (CAFS) on engineered organotropic metastases; (3) evaluate quality and consistency of engineered human bone/liver/lung organotropic metastases assay platform; (4) test stage IV breast cancer standard-of-care drugs in combination with therapies targeting matrix components. After successful completion of the fast track project, xylyx will commercialize the metastatic breast cancer assay platform for scientists in pharma companies in need of predictive metastatic disease models for drug screening, thus reducing the massive costs associated with late- stage attrition due to poor efficacy, and facilitating development of better treatment options for the 270,000+ patients diagnosed with metastatic breast cancer every year. As the industry leader in ECM-based reagents and assays, xylyx will market the product worldwide in the rapidly growing cell-based assay market ($24.6B in 2022, cagr: 12.7%, projected $60.3B by 2030), advancing drug development in the $4.2B breast cancer drug market.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,003,395 | |
| Amendment | $966,420 | |
| Amendment | $295,604 | |
| Original award | $295,604 |
Quick answers
Who received award R44CA287881?
R44CA287881 was awarded to Xylyx Bio, Inc. by National Cancer Institute (National Institutes of Health) on June 6, 2024.
How much is award R44CA287881 worth?
$2,561,023 has been obligated on R44CA287881.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award